# Patient Care Plan

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Barbara Jordan (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML030-SYN-TD
- Date: 1980-03-02
- Fictional facility: St. Posthumous Health Center
- Fictional author: Evangeline Moss, MD
- Calendar frame: true historical dates (modern content is anachronistic)

> True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

## What we are working on

- She wants to keep teaching and speaking without her health becoming the subject **S**
- She wants to know whether any treatment can slow the disease **S**
- She wants to stay safe on her feet and to have energy left at the end of a teaching day **S**

## Your goals

- Diagnosis confirmed and classified, vaccines completed at least two weeks before therapy, and a disease-modifying therapy started within ten weeks. Target: 1980-06-29. Recorded outcome: Primary progressive disease confirmed at two weeks; vaccines finished at five weeks; ocrelizumab started at nine weeks. **S**
- No falls through eight months. Target: 1980-10-26. Recorded outcome: No falls; one near-fall in the summer heat. **S**
- 25-hydroxyvitamin D at least 30 ng/mL within four months. Target: 1980-06-29. Recorded outcome: 34 ng/mL at four months. **S**
- Up no more than once a night to pass urine within three months. Target: 1980-06-29. Recorded outcome: Once a night or less on mirabegron. **S**
- Keep her full teaching and speaking schedule with the accommodations she chooses. Target: 1980-10-26. Recorded outcome: Full schedule kept; accessible rooms, seating and parking in place. **S**
- No new or enlarging T2 lesions on the re-baseline MRI. Target: 1980-10-26. Recorded outcome: No new or enlarging T2 lesions. **S**

## What we agreed to do

- Confirm and classify the diagnosis: MRI of the brain and the cervical and thoracic spine with gadolinium to the MAGNIMS-CMSC-NAIMS protocol, read against the 1971 McDonald criteria; exclude mimics with vitamin B12, TSH and HIV; request the records of the original evaluation. Guideline: Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria (Thompson AJ, et al.; PMID 29275977) (2017); 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis (Wattjes MP, et al.; PMID 34139157) (2021) **S**
- Neurology (multiple sclerosis) consultation to confirm and classify the disease and advise on disease-modifying therapy, its monitoring, vaccination, symptom care and MRI follow-up. Guideline: Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis (Rae-Grant A, et al.; PMID 29686116) (2018); Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria (Thompson AJ, et al.; PMID 29275977) (2017); 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis (Wattjes MP, et al.; PMID 34139157) (2021) **S**
- Screening before any disease-modifying therapy: hepatitis B surface antigen, core antibody and surface antibody; quantitative immunoglobulins; liver tests; blood count with lymphocytes; varicella and measles immunity; tuberculosis blood test; HIV and hepatitis C; JC virus antibody; and vaccines brought up to date, inactivated vaccines at least two weeks and live vaccines at least four weeks before the first dose. Guideline: Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis (Rae-Grant A, et al.; PMID 29686116) (2018); Practice guideline update summary: Vaccine-preventable infections and immunization in multiple sclerosis (Farez MF, et al.; PMID 31462584) (2019); Adult Immunization Schedule by Age (2026) **S**
- Relapse and pseudo-relapse plan: new or worsening symptoms lasting more than 24 hours without fever or heat mean a same-day call; check for urinary infection and fever first, because infection and heat can bring back old symptoms; written card for her bag. Guideline: Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis (Rae-Grant A, et al.; PMID 29686116) (2018); Multiple sclerosis in adults: management (NG220) (2022) **S**
- Mobility, spasticity and falls: physical therapy evaluation for gait, strengthening, stretching, balance and a home exercise program; review of walking aids, with forearm crutches or a rollator and a scooter for long distances when she wants them; home safety review; daily stretching. Guideline: Multiple sclerosis in adults: management (NG220) (2022); CMID: Clinical Monitoring Intelligence Database, osteoporosis and depression monographs (2026) **S**
- Bladder: post-void residual today, timed voiding, fluids earlier in the day, less caffeine, pelvic floor exercises, and a medicine if urgency persists; urine check for any burning, fever or sudden worsening. Guideline: Multiple sclerosis in adults: management (NG220) (2022) **S**
- Fatigue and heat sensitivity: energy conservation and pacing with an occupational therapy review, teaching sessions placed in the morning where she chooses, cooling garments, air conditioning, cool drinks, and aerobic exercise such as pool exercise in cool water. Guideline: Multiple sclerosis in adults: management (NG220) (2022) **S**
- Work: a letter to her employer, with her consent, describing her functional needs (an accessible teaching room near an elevator, a chair and lectern for lectures, reserved parking near her building, and flexibility for medical appointments) without naming the diagnosis; she decides what to disclose. Guideline: Accommodation and Compliance: Multiple Sclerosis (2026); Introduction to the Americans with Disabilities Act (2026) **S**
- Bone health: vitamin D3 with a recheck, calcium from food, weight-bearing exercise, fall prevention, and bone density at the preventive visit because of reduced mobility and earlier steroid courses. Guideline: Multiple sclerosis in adults: management (NG220) (2022); CMID: Clinical Monitoring Intelligence Database, osteoporosis and depression monographs (2026) **S**
- Mood and cognition: PHQ-9 at intake and every six months; ask about concentration and word-finding; counseling offered at any time. Guideline: Multiple sclerosis in adults: management (NG220) (2022); Depression and Suicide Risk in Adults: Screening (2023); CMID: Clinical Monitoring Intelligence Database, osteoporosis and depression monographs (2026) **S**
- On the consultant's advice: ocrelizumab 300 mg on day 1 and day 15 and then 600 mg every 6 months, after the vaccines and at least two weeks after the last inactivated dose, with premedication and observation; blood count and immunoglobulins before each dose; a re-baseline brain MRI three to six months after the first dose and then yearly; baclofen titrated to 10 mg three times a day; mirabegron with a blood pressure check at each visit. Guideline: Practice guideline recommendations summary: Disease-modifying therapies for adults with multiple sclerosis (Rae-Grant A, et al.; PMID 29686116) (2018); 2021 MAGNIMS-CMSC-NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis (Wattjes MP, et al.; PMID 34139157) (2021); OCREVUS (ocrelizumab) injection, prescribing information (2026); Multiple sclerosis in adults: management (NG220) (2022) **S**

## Follow-up

- 1980-03-02: Establishing primary care for multiple sclerosis diagnosed elsewhere: walking, spasticity, bladder, fatigue and heat sensitivity, work, bone health, mood, and the work-up and screening before any disease-modifying therapy **S**
- 1980-03-16: Two-week review with MRI of the brain and spine and the neurology (multiple sclerosis) consultation; vaccines before therapy **S**
- 1980-04-20: Five-week review: second vaccine doses, baclofen titration, physical therapy and readiness for the first infusion **S**
- 1980-06-29: Four-month review, six weeks after the first ocrelizumab doses: infusion tolerance, infections, blood counts, vitamin D, heat and mood **S**
- 1980-08-17: Periodic adult preventive visit **S**
- 1980-10-26: Eight-month review before the first full ocrelizumab dose: re-baseline brain MRI, blood counts and immunoglobulins, seasonal vaccines, mobility and work **S**

This teaching document does not replace care from a qualified clinician.
